Evidence map›Paper›PMID 39140601›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Contributions of the ADNI Biostatistics Core.

Laurel A Beckett, Naomi Saito, Michael C Donohue, Danielle J Harvey, Alzheimer's Disease Neuroimaging Initiative

Abstract readReview
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Nuclear medicine and molecular imaging · 2025
    Article
  6. Article
  7. Article
  8. Contributions of the ADNI Biostatistics Core.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laurel A BeckettDepartment of Public Health Sciences, University of California, Davis, California, USA.
Naomi SaitoDepartment of Public Health Sciences, University of California, Davis, California, USA.
Michael C DonohueDepartment of Neurology, University of Southern California, Los Angeles, California, USA.
Danielle J HarveyDepartment of Public Health Sciences, University of California, Davis, California, USA.
Alzheimer's Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Duygu Tosun-Turgut · 2016 to 2026
$226.7M
UC Davis Alzheimer's Disease Research CenterP30AG072972 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Charles DeCarli, Rachel A Whitmer · 2021 to 2026
$25.2M
AbbVieAlzheimer's AssociationAlzheimer's Drug Discovery FoundationAraclon BiotechBioClinica, Inc.BiogenBristol-Myers Squibb CompanyCereSpir, Inc.CIHRCogstateEisai Inc.Elan Pharmaceuticals, Inc.Eli Lilly and CompanyEuroImmunF. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.Foundation for the National Institutes of HealthFujirebioGE HealthcareIXICO Ltd.Janssen Alzheimer Immunotherapy Research & Development, LLCJohnson & Johnson Pharmaceutical Research &Development LLCLumosityLundbeckMerck & Co., Inc.Meso Scale Diagnostics, LLCNeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS P30 AG072972NIA NIH HHS U19 AG024904NIBIB NIH HHSNIH HHS U19 AG024904Northern California Institute for Research and EducationNovartis Pharmaceuticals CorporationPfizer Inc.Piramal ImagingServierTakeda Pharmaceutical CompanyTransition Therapeutics
6 · The paper itself

Abstract

The goal of the Biostatistics Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been to ensure that sound study designs and statistical methods are used to meet the overall goals of ADNI. We have supported the creation of a well-validated and well-curated longitudinal database of clinical and biomarker information on ADNI participants and helped to make this accessible and usable for researchers. We have developed a statistical methodology for characterizing the trajectories of clinical and biomarker change for ADNI participants across the spectrum from cognitively normal to dementia, including multivariate patterns and evidence for heterogeneity in cognitive aging. We have applied these methods and adapted them to improve clinical trial design. ADNI-4 will offer us a chance to help extend these efforts to a more diverse cohort with an even richer panel of biomarker data to support better knowledge of and treatment for Alzheimer's disease and related dementias. HIGHLIGHTS: The Alzheimer's Disease Neuroimaging Initiative (ADNI) Biostatistics Core provides study design and analytic support to ADNI investigators. Core members develop and apply novel statistical methodology to work with ADNI data and support clinical trial design. The Core contributes to the standardization, validation, and harmonization of biomarker data. The Core serves as a resource to the wider research community to address questions related to the data and study as a whole.

Indexed as

Alzheimer DiseaseBiostatisticsNeuroimagingBiomarkersDatabases, FactualHumansLongitudinal StudiesMaleResearch DesignBiomarkersAlzheimer's Disease Neuroimaging Initiativebiomarker progressionbiomarker validationclinical trial designdata standardization

Identifiers

PMID39140601
PMCPMC11485306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.